Revenue - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Epizyme Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Epizyme Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
E
Epizyme Inc
F:EPE
Revenue
$53m
CAGR 3-Years
31%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55B
CAGR 3-Years
1%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.8B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Revenue
$30.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.3B
CAGR 3-Years
16%
CAGR 5-Years
25%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.5B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
18%

Epizyme Inc
Revenue Breakdown

Breakdown by Geography
Epizyme Inc

Not Available

Breakdown by Segments
Epizyme Inc

Total Revenue: 37.4m USD
100%
Product: 30.9m USD
82.6%
Collaboration Revenue: 6.5m USD
17.4%

See Also

What is Epizyme Inc's Revenue?
Revenue
53m USD

Based on the financial report for Jun 30, 2022, Epizyme Inc's Revenue amounts to 53m USD.

What is Epizyme Inc's Revenue growth rate?
Revenue CAGR 5Y
25%

Over the last year, the Revenue growth was 63%. The average annual Revenue growth rates for Epizyme Inc have been 31% over the past three years , 25% over the past five years .

Back to Top